Biomerica, Inc. (NASDAQ:BMRA) Short Interest Update

Biomerica, Inc. (NASDAQ:BMRAGet Free Report) saw a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 562,400 shares, a growth of 50.5% from the October 15th total of 373,700 shares. Based on an average daily volume of 446,300 shares, the short-interest ratio is currently 1.3 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Biomerica stock. Perritt Capital Management Inc acquired a new position in Biomerica, Inc. (NASDAQ:BMRAFree Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 70,000 shares of the company’s stock, valued at approximately $31,000. Perritt Capital Management Inc owned 0.42% of Biomerica as of its most recent filing with the Securities & Exchange Commission. 22.28% of the stock is currently owned by hedge funds and other institutional investors.

Biomerica Stock Performance

NASDAQ BMRA remained flat at $0.35 on Friday. 48,227 shares of the company were exchanged, compared to its average volume of 232,134. The stock has a market cap of $5.87 million, a price-to-earnings ratio of -0.92 and a beta of -1.13. The business has a fifty day moving average of $0.33 and a 200 day moving average of $0.42. Biomerica has a 52 week low of $0.24 and a 52 week high of $2.13.

Biomerica (NASDAQ:BMRAGet Free Report) last posted its earnings results on Tuesday, October 15th. The company reported ($0.08) earnings per share (EPS) for the quarter. The business had revenue of $1.81 million for the quarter. Biomerica had a negative net margin of 111.89% and a negative return on equity of 84.62%.

Biomerica Company Profile

(Get Free Report)

Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.

Featured Articles

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.